Citation Impact
Citing Papers
Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America
2010 Standout
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
2007 Standout
Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial
2011
Théorie des distributions à valeurs vectorielles. I
1957
Early Versus Delayed Antiretroviral Therapy and Cerebrospinal Fluid Fungal Clearance in Adults With HIV and Cryptococcal Meningitis
2013 StandoutNobel
Antifungal Agents in the 1990s
1997
Antifungal Drug Resistance in Aspergillus
2000
Vulvovaginal candidosis
2007 Standout
Cryptococcal Neuroradiological Lesions Correlate with Severity during Cryptococcal Meningoencephalitis in HIV-Positive Patients in the HAART Era
2008
Melioidosis
2018 Standout
Inhibition of human pathogenic fungi by ethnobotanically selected plant extracts
2003
Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): A review of recent research
2007 Standout
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
2009 Standout
Funicone-related Compounds, Potentiators of Antifungal Miconazole Activity, Produced by Talaromyces flavus FKI-0076.
2002 StandoutNobel
CNS pharmacokinetics of antifungal agents
2007
Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
2017 Standout
Virulence factors of Candida albicans
2001 Standout
Defensins: antimicrobial peptides of innate immunity
2003 Standout
Fungal infections of the skin and nail: new treatment options
2014
Phylogenetic Species Recognition and Species Concepts in Fungi
2000 Standout
Prevalence, Determinants of Positivity, and Clinical Utility of Cryptococcal Antigenemia in Cambodian HIV-Infected Patients
2007
Evaluation of a Novel Point-of-Care Cryptococcal Antigen Test on Serum, Plasma, and Urine From Patients With HIV-Associated Cryptococcal Meningitis
2011
Mechanisms of Fungal Resistance
2002
Immunocompromised Hosts: Cryptococcosis in Solid Organ Transplant Recipients: Current State of the Science
2008
Fungal infections in solid organ transplantation
2007
Liquid/liquid extraction using 96-well plate format in conjunction with hydrophilic interaction liquid chromatography–tandem mass spectrometry method for the analysis of fluconazole in human plasma
2003
Cryptococcus neoformansInfection in Organ Transplant Recipients: Variables Influencing Clinical Characteristics and Outcome
2001
Cryptococcosis in Organ Transplant Recipients: An Overview
2002
Isolation and characterization of capsule structure mutant strains of Cryptococcus neoformans
2002
PI3K signaling of autophagy is required for starvation tolerance and virulenceof Cryptococcus neoformans
2008 StandoutNobel
Hydrophilic interaction chromatography
2006 Standout
Paradoxical roles of alveolar macrophages in the host response to Cryptococcus neoformans
2011
Evolution of Antifungal Susceptibility amongCandidaSpecies Isolates Recovered from Human Immunodeficiency Virus–Infected Women Receiving Fluconazole Prophylaxis
2001
Cryptococcosis
2006
Lower limb cellulitis and its mimics
2012
Major Role for Amphotericin B–Flucytosine Combination in Severe Cryptococcosis
2008
Resistance to Antibiotics: Are We in the Post-Antibiotic Era?
2005 Standout
Glucocorticoids and invasive fungal infections
2003
Emerging fungal resistance
2004
Cryptococcus gattii:in vitrosusceptibility to the new antifungal albaconazole versus fluconazole and voriconazole
2005
Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy
2006
Echinocandin antifungal drugs
2003 Standout
Itraconazole: pharmacology, clinical experience and future development
1996
The role of serum cryptococcal antigen screening for the early diagnosis of cryptococcosis in HIV-infected patients with different ranges of CD4 cell counts
2010
The Future of Antifungal Therapy
1996
Spleen deposition ofCryptococcus neoformanscapsular glucuronoxylomannan in rodents occurs in red pulp macrophages and not marginal zone macrophages expressing the C-type lectin SIGN-R1
2008 StandoutNobel
Cryptococcus gattiiInfection: Characteristics and Epidemiology of Cases Identified in a South African Province with High HIV Seroprevalence, 2002–2004
2006
In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs
2006
The origin and maintenance of virulence for the human pathogenic fungus Cryptococcus neoformans
2003
Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS
2009 Standout
Management of Chronic Kidney Disease Patients in the Intensive Care Unit: Mixing Acute and Chronic Illness
2017 Standout
Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France
2005
Interleukin-23 Promotes a Distinct CD4 T Cell Activation State Characterized by the Production of Interleukin-17
2003 Standout
Epidemiology of Cryptococcal Meningitis in the US: 1997–2009
2013
Voriconazole: A New Triazole Antifungal Agent
2003 Standout
Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence
2006
Cyclodextrin-based pharmaceutics: past, present and future
2004 Standout
Determinants of Disease Presentation and Outcome during Cryptococcosis: The CryptoA/D Study
2007
Sexually transmitted diseases treatment guidelines
2003 Standout
Epidemiology of Cryptococcosis in France: A 9-Year Survey (1985-1993)
1996
Itraconazole
1996
Cas1p is a membrane protein necessary for the O‐acetylation of the Cryptococcus neoformans capsular polysaccharide
2001
Screening for Cryptococcal Antigenemia in Patients Accessing an Antiretroviral Treatment Program in South Africa
2009
Cryptococcosis
2002
Strategies to reduce mortality and morbidity due to AIDS-related cryptococcal meningitis in Latin America
2013
Tie2-dependent VHL knockdown promotes airway microvascular regeneration and attenuates invasive growth of Aspergillus fumigatus
2013 StandoutNobel
CNS pharmacokinetics of antifungal agents
2007
Antifungal drug resistance
1995
Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America
2014 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.
2009
Sexually Transmitted Infections Treatment Guidelines, 2021
2021 Standout
Efficacy of Amphotericin B in Combination with Flucytosine against Flucytosine-Susceptible or Flucytosine-Resistant Isolates of Cryptococcus neoformans during Disseminated Murine Cryptococcosis
2005
2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis
2016 Standout
Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections
2005
Cryptococcus neoformans var. grubii : Separate Varietal Status for Cryptococcus neoformans Serotype A Isolates
1999
Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance
1999 Standout
Sexually Transmitted Diseases Treatment Guidelines, 2010
2011 Standout
Current and Emerging Azole Antifungal Agents
1999 Standout
Organism-Dependent Fungicidal Activities of Azoles
1998
Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children
2011 Standout
Cellulitis
2016
Bloodstream infections in HIV-infected patients
2016
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
1998
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
2015 Standout
Interleukin-12 Is Essential for a Protective Th1 Response in Mice Infected withCryptococcus neoformans
1998
Hemicelluloses
2010 Standout
Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain
1995
Candida glabrata : Review of Epidemiology, Pathogenesis, and Clinical Disease with Comparison to C. albicans
1999
Compact sets in the spaceL p (O,T; B)
1986 Standout
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
2005 Standout
Results Obtained with Various Antifungal Susceptibility Testing Methods Do Not Predict Early Clinical Outcome in Patients with Cryptococcosis
2006
Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections
2010 Standout
Aspergillus fumigatusand Aspergillosis
1999 Standout
Cryptococcus neoformansInfection in Organ Transplant Recipients: Variables Influencing Clinical Characteristics and Outcome
2001
Cryptococcus neoformansVirulence Is Enhanced after Growth in the Genetically Malleable HostDictyostelium discoideum
2003
Immunogenicity and Efficacy ofCryptococcus neoformansCapsular Polysaccharide Glucuronoxylomannan Peptide Mimotope-Protein Conjugates in Human Immunoglobulin Transgenic Mice
2003
Burn Wound Infections
2006 Standout
Human Salivary Histatins: Promising Anti-Fungal Therapeutic Agents
1998
Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene
1997
Cyclic AMP-Dependent Protein Kinase Controls Virulence of the Fungal Pathogen Cryptococcus neoformans
2001
Guidelines for Treatment of Candidiasis
2004 Standout
Hidden Killers: Human Fungal Infections
2012 Standout
Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans
1995 Standout
Efficacy of LY303366 against Amphotericin B-Susceptible and -Resistant Aspergillus fumigatus in a Murine Model of Invasive Aspergillosis
1998
Galleria mellonella as a Model System To Study Cryptococcus neoformans Pathogenesis
2005 Standout
Macrophage plasticity, polarization, and function in health and disease
2018 Standout
A multicentre pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France during 1998-1999
2004
Works of O. Ronin being referenced
Transformation de Laplace
2013
Primary Cutaneous Cryptococcosis: A Distinct Clinical Entity
2003
Individual and Environmental Factors Associated with Infection Due to Cryptococcus neoformans Serotype D
1996
Fluconazole, with or without dexamethasone for experimental cryptococcosis: impact of treatment timing
1999
Mechanisms and clinical impact of antifungal drug resistance
1994
Epidemiology of HIV-associated cryptococcosis in France (1985–2001)
2004
Serotyping of Cryptococcus neoformans by using a monoclonal antibody specific for capsular polysaccharide
1993
Molecular typing of Cryptococcus neoformans serotype D clinical isolates
1994
Evaluation of a monoclonal antibody-based latex agglutination test for diagnosis of cryptococcosis: comparison with two tests using polyclonal antibodies
1992
Isolation ofCryptococcus neoformansvar.gattiifrom an asian patient in France: evidence for dormant infection in healthy subjects
1992
DNA typing suggests pigeon droppings as a source of pathogenic Cryptococcus neoformans serotype D
1997